Abstract
We investigated the effect of BAY u3405, a thromboxane A2 receptor antagonist in pentobarbital anaesthetized rats subjected to left main coronary artery ligation (1 h) followed by reperfusion (1 h; MI/R). Sham operated rats were used as controls (Sham MI/R). Survival rate, myocardial necrosis, myocardial myeloperoxidase activity (investigated as an index of leukocyte adhesion and accumulation) and serum creatine phosphokinase activity were studied. Ischaemia-reperfusion injury significantly reduced the survival rate (45%), caused a marked myocardial necrosis, increased serum creatine phosphokinase activity (Sham MI/R=26±10.2 U/ml; MI/R=213±19 U/ml) and produced a rise in myocardial myeloperoxidase activity in the area-at-risk and in the necrotic area (6.1±0.4 U×10−3/g tissue and 6.7±0.9 U×10−3/g of tissue, respectively).
The administration of BAY u3405 (30 and 60 mg/kg/i.v., 30 min before occlusion) significantly increased survival rate, lowered the area of myocardial necrosis, blunted the increase in serum creatine phosphokinase activity and reduced the increase in myeloperoxidase activity in both the area-at-risk and the necrotic area. Furthermore, the protective effect of BAY u3405 was dose-dependent.
These data are consistent with an involvement of TXA2 in myocardial ischaemia-reperfusion injury and suggest that BAY u3405 may represent a novel therapeutic approach to the treatment of acute ischaemia-reperfusion injury.
Similar content being viewed by others
References
E. F. Smith III, A. M. Lefer and J. B. Smith,Influence of thromboxane inhibition on the severity of myocardial ischemia in cats. Can. J. Physiol. Pharmacol.58, 294–300 (1980).
A. M. Lefer,Significance of lipid mediators in shock states. Circ. Shock27, 3–12 (1989).
P. Walinsky, J. B. Smith and A. M. Lefer et al.,Thromboxane A 2 in acute myocardial infarction. Am. Heart J.108, 868–872 (1984).
S. Morooka, M. Kobayashi and T. Shimamoto,Experimental ischemic heart disease induced by thromboxane A 2 in rabbits. Jap. Circ. J.41, 1373–1379 (1978).
E. F. Smith III, A. M. Lefer and D. Aharony et al.,Carbocyclic thromboxane A 2 : Aggravation of myocardial ischemia by a new synthetic thromboxane analog. Prostaglandins21, 443–456 (1981).
S. E. Burke, G. DiCola and A. M. Lefer,Protection of ischemic cat myocardium by CGS-13080, a selective potent thromboxane A 2 synthesis inhibitor. J. Cardiovasc. Pharmacol.5, 842–847 (1983).
B. M. Lucchesi,Modulation of leukocyte-mediated myocardial reperfusion injury. Annu. Rev. Physiol.52, 561 (1990).
P. M. Vanhoutte and D. S. Houston,Platelets, endothelium and vasopasm. Circulation72, 728–735 (1985).
A. M. Lefer and H. Darius,A pharmacological approach to thromboxane receptor antagonism. Fed. Proc.46, 144–148 (1987).
E. Perzborn, F. Seuter, V. B. Fiedler, U. Rosentreter and H. B. Shagen,Action of the novel selective Thromboxane antagonist (3R)-3(4-Fluorophenylsulfonamido)-1, 2. 3, 4-tetrahydro-9-carbozole-propanoic acid on vascular smooth muscle preparations. Arzneim Forsch/Drug Res.39(II), 1522–1525 (1989).
X. Norel, C. Labat, P. J. Gardiner and C. Brink,Inhibitory effects of BAY u3405 on prostanoid-induced contractions in human isolated bronchila and pulmonary arterial muscle preparations Br. J. Pharmacol.104, 591–595 (1991).
P. H. Rounding and V. B. Fiedler,Improved coronary thrombolysis by tissue-type plasminogen activator in the presence of BAY u3405. Eur. J. Pharmacol.198, 207–210 (1991).
H. P. Francis, S. J. Greenham, U. P. Patel, A. M. Thompson and P. J. Gardiner,BAY u3405 an antagonist of thromboxane A 2 and prostaglandin D 2 induced bronchoconstriction in the guinea-pig. Br. J. Pharmacol.104, 596–602 (1991).
A. P. Caputi, F. Rossi, F. Carney and H. E. Brezenoff,Modulatory effect of brain acetylcholine on reflex-induced bradycardia and tachycardia in conscious rats. J. Pharmacol. Exp. Ther.215, 309–316 (1980).
M. A. Petty, J. Dow, J. M. Grisar and W. De Jong,Effect of a cardioselective α-tocopherol analogue on reperfusion injury in rats induced by myocardial ischemia. Eur. J. Pharmacol.192, 383–388 (1991).
S. B. Rosalki,An improved procedure for serum creatine phosphokinase determination. J. Lab. Clin. Med.69, 696–705 (1967).
K. M. Mullane, R. Kraemer and B. Smith,Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into isochemic myocardium. J. Pharmacol. Meth.14, 157–167 (1985).
A. M. Lefer, G. Johnson III, M. Xin-Liang, P. S. Tsao and G. R. Thomas,Cardioprotective and endothelial protective effects of [Ala-IL8] in a rabbit model of myocardial ischemia and reperfusion. Br. J. Pharmacol.103, 1153–1159 (1991).
D. E. Griswold, L. M. Hillegass, D. E. Hill, J. W. Egan and E. F. Smith III,Method for quantification of myocardial infarction and inflammatroy cell infiltration in rat cardiac tissue. J. Pharmacol. Meth.20, 225–235 (1988).
S. J. Coker, J. R. Parratt,AH 23848, a thromboxane receptor antagonist suppresses ischemic and reperfusion-induced arrhythmias in anesthetized greyhounds. Br. J. Pharmacol.86, 259–264 (1985).
P. Braquet, L. Touqui, T. Y. Shen and G. G. Vargaftig,Perspectives in platelet-activating factor research. Pharmacol. Rev.39, 97–145 (1987).
G. Feuerstein,Leukotrienes and the cardiovascular system. Prostaglandins27, 781–802 (1984).
J. M. McCord,Oxygen-derived free radicals in post ischemic tissue injury. New Engl. J. Med.312, 159–163 (1985).
J. L. Mehta, W. W. Nichols and P. Mehta,Neutrophils as potential participants in acute myocardial ischemia: Relevance to reperfusion. J. Am. Coll. Cardiol.11, 1309–1316 (1988).
J. L. Dinerman and J. L. Mehta,Endothelial, platelet and leukocyte interactions in ischemic heart disease: Insights into potential mechanisms and their clinical relevance. J. Am. Coll. Cardiol.16, 207–222 (1990).
K. M. Mullane, J. A. Salmon and S. Moncada,Role of leukocytes in acute myocardial infarction in anesthetized dogs: Relationship to myocardial salvage by anti-inflammatory drugs. J. Pharmacol. Exp. Ther.510, 510–522 (1984).
R. Engler and J. W. Covell,Granulocytes cause reperfusion ventricular dysfunction after 15 minute ischemia in the dog. Circ. Res.61, 20–28 (1987).
J. L. Romson, B. G. Hook, V. H. Rigot, M. A. Schork, D. P. Swanson and B. R. Lucchesi,The effect of ibuprofen on accumulation of indium-111-labeled platelets and leukocytes in experimental myocardial infarction. Circulation66, 1002–1011 (1982).
F. Squadrito et al.,Protective effects of G-619, a dual thromboxane synthase inhibitor and thromboxane A 2 receptor antagonist, in splanchnic artery occlusion shock. J. Cardiovasc. Pharmacol.19, 115–119 (1992).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Squadrito, F., Ioculano, M., Altavilla, D. et al. Reduction of myocardial leukocyte accumulation and myocardial infarct size following administration of BAY u3405, a thromboxane A2 receptor antagonist, in myocardial ischaemia-reperfusion injury. Agents and Actions 39, 143–149 (1993). https://doi.org/10.1007/BF01998967
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01998967